Sanofi to acquire Kiadis and NK cell tech for $353 millionSanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) Share XSanofi to acquire Kiadis and NK cell tech for $353 millionhttps://pharmaphorum.com/news/sanofi-to-acquire-kiadis-and-nk-cell-tech-for-353-million/
Coronavirus pharma news round-up 21/08/20New insights into smell and taste loss symptoms, artificial intelligence and further encouraging data from a vaccine candidate Share XCoronavirus pharma news round-up 21/08/20https://pharmaphorum.com/views-and-analysis/coronavirus-pharma-news-round-up-21-08-20/
Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myelomaSanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells Share XKiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myelomahttps://pharmaphorum.com/news/sanofi-to-develop/
